We’re on a mission to fulfill the promise of genetic medicine for all patients
At Addition, we are advancing a pipeline of therapeutics to deliver functional cures for patients with severe lifelong diseases in large and rare populations.
Our CSO Francine Gregoire, PhD, will participate in the Beyond CRISPR virtual panel at Endpoints Discovery Day 2026 on April 15 from 11:00 - 11:25 am ET.
Learn more about Endpoints Discovery Day 2026 and register HERE
About Us
Today, the field of genetic medicine is composed of two primary modalities: RNA therapeutics and viral-based gene therapies. Both modalities have delivered important advances for patients, but each is limited to distinct applications.
At Addition, we are combining the safety, efficacy and scalability profile of RNA therapeutics with the multi-year durability of viral-based gene therapies.
Our best of both modalities approach — enabled by our PRINT technology — has the potential to further unlock the potential of genetic medicines and deliver functional cures for patients with severe lifelong diseases.
We’re focused initially on rare patient populations with severe, life-threatening unmet needs, with the goal of ultimately also addressing larger, related patient populations.
Promise
We’re committed to transformational impact for patients.
